NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco next week. Andrea Riposati, CEO of Dante Genomics, will present on Tuesday, January 10, 2023 at 4:30 PM Pacific Time at The Westin St. Francis.
“We are thrilled to be presenting at the J.P. Morgan Healthcare Conference this year,” said Andrea Riposati, co-founder and CEO of Dante Genomics. “The future of healthcare needs whole genome sequencing, and I look forward to attending the conference and sharing how Dante Genomics is impacting lives around the world with whole genome sequencing.”
The Annual J.P. Morgan Healthcare Conference is by invitation only, and it is the premier financial event of the year in healthcare. The conference is one of the largest and most informative healthcare investment symposiums in the industry connecting global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Contact:
Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
